Literature DB >> 26778714

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

Aditya Bagrodia1, Eugene K Cha1,2, John P Sfakianos3, Emily C Zabor4, Bernard H Bochner1,2, Hikmat A Al-Ahmadie5, David B Solit2,6,7, Jonathan A Coleman1,2, Gopa Iyer2,6,7, Sasinya N Scott7, Ronak Shah7, Irina Ostrovnaya4, Byron Lee1, Neil B Desai7, Qinghu Ren5, Jonathan E Rosenberg2,6,7, Guido Dalbagni1,2, Dean F Bajorin2,6,7, Victor E Reuter5, Michael F Berger5,7.   

Abstract

PURPOSE: Genomic characterization of radical nephroureterectomy specimens in patients with upper tract urothelial carcinoma may allow for thoughtful integration of systemic and targeted therapies. We sought to determine whether genomic alterations in upper tract urothelial carcinoma are associated with adverse pathological and clinical outcomes.
MATERIALS AND METHODS: Next generation exon capture sequencing of 300 cancer associated genes was performed in 83 patients with upper tract urothelial carcinoma. Genomic alterations were assessed individually and also grouped into core signal transduction pathways or canonical cell functions for association with clinicopathological outcomes. Binary outcomes, including grade (high vs low), T stage (pTa/T1/T2 vs pT3/T4) and organ confined status (pT2 or less and N0/Nx vs greater than pT2 or N+) were assessed with the Kruskal-Wallis and Fisher exact tests as appropriate. Associations between alterations and survival were estimated using the Kaplan-Meier method and Cox regression.
RESULTS: Of the 24 most commonly altered genes in 9 pathways TP53/MDM2 alterations and FGFR3 mutations were the only 2 alterations uniformly associated with high grade, advanced stage, nonorgan confined disease, and recurrence-free and cancer specific survival. TP53/MDM2 alterations were associated with adverse clinicopathological outcomes whereas FGFR3 mutations were associated with favorable outcomes. We created a risk score using TP53/MDM2 and FGFR3 status that was able to discriminate between adverse pathological and clinical outcomes, including in the subset of patients with high grade disease. The study is limited by small numbers and lack of validation.
CONCLUSIONS: Our data indicate that specific genomic alterations in radical nephroureterectomy specimens correlate with tumor grade, stage and cancer specific survival outcomes.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biological markers; carcinoma; genomics; kidney; ureter

Mesh:

Substances:

Year:  2016        PMID: 26778714      PMCID: PMC4871772          DOI: 10.1016/j.juro.2016.01.006

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Genomic Characterization of Upper Tract Urothelial Carcinoma.

Authors:  John P Sfakianos; Eugene K Cha; Gopa Iyer; Sasinya N Scott; Emily C Zabor; Ronak H Shah; Qinghu Ren; Aditya Bagrodia; Philip H Kim; A Ari Hakimi; Irina Ostrovnaya; Ricardo Ramirez; Aphrothiti J Hanrahan; Neil B Desai; Arony Sun; Patrizia Pinciroli; Jonathan E Rosenberg; Guido Dalbagni; Nikolaus Schultz; Dean F Bajorin; Victor E Reuter; Michael F Berger; Bernard H Bochner; Hikmat A Al-Ahmadie; David B Solit; Jonathan A Coleman
Journal:  Eur Urol       Date:  2015-08-14       Impact factor: 20.096

Review 2.  Urothelial tumorigenesis: a tale of divergent pathways.

Authors:  Xue-Ru Wu
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

3.  Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma.

Authors:  Aditya Bagrodia; Ramy F Youssef; Payal Kapur; Oussama M Darwish; Chase Cannon; Michael J Belsante; Deniz Gerecci; Arthur I Sagalowsky; Shahrokh F Shariat; Yair Lotan; Vitaly Margulis
Journal:  Eur Urol       Date:  2012-04-17       Impact factor: 20.096

4.  The p53-mdm-2 autoregulatory feedback loop.

Authors:  X Wu; J H Bayle; D Olson; A J Levine
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

Review 5.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

6.  Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.

Authors:  Pierre I Karakiewicz; Shahrokh F Shariat; Ganesh S Palapattu; Amiel E Gilad; Yair Lotan; Craig G Rogers; Amnon Vazina; Amit Gupta; Patrick J Bastian; Paul Perrotte; Arthur I Sagalowsky; Mark Schoenberg; Seth P Lerner
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

7.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

8.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

Authors:  Bernard H Bochner; Michael W Kattan; Kinjal C Vora
Journal:  J Clin Oncol       Date:  2006-07-24       Impact factor: 44.544

9.  Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.

Authors:  Vitaly Margulis; Shahrokh F Shariat; Surena F Matin; Ashish M Kamat; Richard Zigeuner; Eiji Kikuchi; Yair Lotan; Alon Weizer; Jay D Raman; Christopher G Wood
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

View more
  12 in total

1.  Diagnostic role of urine cytology and ureteroscopic biopsies in detection of high grade upper tract urothelial carcinoma.

Authors:  Yani Zhao; Fang-Ming Deng; Jonathan Melamed; William C Huang; Hongying Huang; Qinghu Ren
Journal:  Am J Clin Exp Urol       Date:  2021-06-15

2.  Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.

Authors:  Brian R Winters; Navonil De Sarkar; Sonali Arora; Hamid Bolouri; Sujata Jana; Funda Vakar-Lopez; Heather H Cheng; Michael T Schweizer; Evan Y Yu; Petros Grivas; John K Lee; Lori Kollath; Sarah K Holt; Lisa McFerrin; Gavin Ha; Peter S Nelson; Robert B Montgomery; Jonathan L Wright; Hung-Ming Lam; Andrew C Hsieh
Journal:  JCI Insight       Date:  2019-05-30

Review 3.  Correlating Preoperative Imaging with Histologic Subtypes of Renal Cell Carcinoma and Common Mimickers.

Authors:  Jennifer Gordetsky; Jessica Zarzour
Journal:  Curr Urol Rep       Date:  2016-07       Impact factor: 3.092

4.  Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder.

Authors:  Yi-Ying Lee; Chieh-Tien Wang; Steven Kuan-Hua Huang; Wen-Jeng Wu; Chun-Nung Huang; Ching-Chia Li; Ti-Chun Chan; Peir-In Liang; Chung-Hsi Hsing; Chien-Feng Li
Journal:  J Cancer       Date:  2016-10-25       Impact factor: 4.207

Review 5.  Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up.

Authors:  Mudhar N Hasan; Morgan Rouprêt; Francis Keeley; Cecilia Cracco; Robert Jones; Michael Straub; Olivier Traxer; Palle Jörn Sloth Osther; Marianne Brehmer
Journal:  World J Urol       Date:  2019-04-03       Impact factor: 4.226

Review 6.  Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.

Authors:  Grzegorz Fojecki; Anders Magnusson; Olivier Traxer; Joyce Baard; Palle Jörn Sloth Osther; Georg Jaremko; Christian Seitz; Thomas Knoll; Guido Giusti; Marianne Brehmer
Journal:  World J Urol       Date:  2019-03-26       Impact factor: 4.226

Review 7.  Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.

Authors:  Elisa De Lorenzis; Giancarlo Albo; Fabrizio Longo; Carolina Bebi; Luca Boeri; Emanuele Montanari
Journal:  Genes (Basel)       Date:  2021-02-25       Impact factor: 4.096

8.  Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts.

Authors:  Kwanghee Kim; Wenhuo Hu; François Audenet; Nima Almassi; Aphrothiti J Hanrahan; Katie Murray; Aditya Bagrodia; Nathan Wong; Timothy N Clinton; Shawn Dason; Vishnu Mohan; Sylvia Jebiwott; Karan Nagar; Jianjiong Gao; Alex Penson; Chris Hughes; Benjamin Gordon; Ziyu Chen; Yiyu Dong; Philip A Watson; Ricardo Alvim; Arijh Elzein; Sizhi P Gao; Emiliano Cocco; Alessandro D Santin; Irina Ostrovnaya; James J Hsieh; Irit Sagi; Eugene J Pietzak; A Ari Hakimi; Jonathan E Rosenberg; Gopa Iyer; Herbert A Vargas; Maurizio Scaltriti; Hikmat Al-Ahmadie; David B Solit; Jonathan A Coleman
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

9.  Prognostic value of preoperative lymphocyte-related systemic inflammatory biomarkers in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: a systematic review and meta-analysis.

Authors:  Yuan Shao; Wenxia Li; Dongwen Wang; Bo Wu
Journal:  World J Surg Oncol       Date:  2020-10-23       Impact factor: 2.754

10.  Prognostic Value of Comorbidity for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy.

Authors:  Hung-Lung Ke; Ching-Chia Li; Hsiang-Ying Lee; Hung-Pin Tu; Yu-Ching Wei; Hsin-Chih Yeh; Wen-Jeng Wu; Wei-Ming Li
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.